SYBX Insider Trading
Insider Ownership Percentage: 2.62%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $284.17
Synlogic Share Price & Price History
Current Price: $0.63
Price Change: ▲ Price Increase of +0.0001 (0.02%)
As of 04/17/2026 12:41 PM ET
Synlogic Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/29/2025 | Mary Beth Dooley | Insider | Sell | 157 | $1.81 | $284.17 | 12,744 |  |
| 2/3/2025 | Mary Beth Dooley | Insider | Sell | 2,107 | $1.33 | $2,802.31 | 13,045 | |
| 10/29/2024 | Mary Beth Dooley | Insider | Sell | 79 | $1.40 | $110.60 | 15,152 | |
| 4/2/2024 | Antoine Awad | COO | Sell | 372 | $1.73 | $643.56 | 33,859 | |
| 4/2/2024 | Mary Beth Dooley | Insider | Sell | 188 | $1.73 | $325.24 | 15,231 | |
Synlogic Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/12/2026 | DRW Securities LLC | 24,363 | $27K | 0.0% | N/A | 0.208% |  |
| 2/12/2026 | Renaissance Technologies LLC | 85,627 | $96K | 0.0% | +116.7% | 0.732% | |
| 11/17/2025 | Citadel Advisors LLC | 29,011 | $49K | 0.0% | N/A | 0.248% | |
| 2/13/2025 | Renaissance Technologies LLC | 22,310 | $31K | 0.0% | -69.0% | 0.191% | |
| 11/13/2024 | FMR LLC | 166,724 | $0.25M | 0.0% | -27.6% | 1.425% | |
| 8/9/2024 | Renaissance Technologies LLC | 100,530 | $0.15M | 0.0% | -15.1% | 0.859% | |
| 2/13/2024 | Armistice Capital LLC | 1,055,000 | $4.06M | 0.1% | +75.9% | 11.480% | |
| 1/8/2024 | Harbor Capital Advisors Inc. | 30,685 | $0.12M | 0.0% | +43.4% | 0.334% | |
| 11/15/2023 | Armistice Capital LLC | 599,874 | $1.69M | 0.0% | N/A | 13.098% | |
| 11/13/2023 | WINTON GROUP Ltd | 12,401 | $35K | 0.0% | N/A | 0.271% | |
| 10/20/2023 | Harbor Capital Advisors Inc. | 21,403 | $60K | 0.0% | -92.6% | 0.467% | |
| 7/31/2023 | PVG Asset Management Corp | 68,455 | $29K | 0.1% | -31.7% | 0.100% | |
| 7/11/2023 | Harbor Capital Advisors Inc. | 290,605 | $0.13M | 0.0% | +10.1% | 0.426% | |
| 4/26/2023 | Harbor Capital Advisors Inc. | 264,026 | $0.17M | 0.0% | -15.3% | 0.387% | |
| 1/13/2023 | Flagship Harbor Advisors LLC | 40,000 | $30K | 0.0% | -28.6% | 0.057% | |
| 11/14/2022 | RA Capital Management L.P. | 4,618,415 | $4.39M | 0.1% | -20.7% | 6.576% | |
| 11/14/2022 | UBS Oconnor LLC | 465,741 | $0.44M | 0.0% | -14.2% | 0.663% | |
| 10/28/2022 | Harbor Capital Advisors Inc. | 318,309 | $0.30M | 0.3% | -10.0% | 0.453% | |
| 8/12/2022 | Ikarian Capital LLC | 474,360 | $0.55M | 0.1% | -8.7% | 0.675% | |
| 8/4/2022 | Royce & Associates LP | 434,041 | $0.50M | 0.0% | -10.3% | 0.618% | |
| 5/5/2022 | UMA Financial Services Inc. | 17,302 | $30K | 0.0% | N/A | 0.025% | |
| 4/28/2022 | Harbor Capital Advisors Inc. | 354,998 | $0.85M | 0.4% | -18.9% | 0.509% | |
| 2/15/2022 | Stonepine Capital Management LLC | 1,064,135 | $2.58M | 1.2% | +6.4% | 1.527% | |
| 2/14/2022 | Opaleye Management Inc. | 850,000 | $2.06M | 0.4% | N/A | 1.219% | |
| 2/14/2022 | LMR Partners LLP | 550,000 | $1.33M | 0.0% | +10.0% | 0.789% | |
| 2/10/2022 | Acadian Asset Management LLC | 77,655 | $0.19M | 0.0% | +796.3% | 0.111% | |
| 2/10/2022 | Connor Clark & Lunn Investment Management Ltd. | 32,161 | $78K | 0.0% | N/A | 0.046% | |
| 2/9/2022 | Dimensional Fund Advisors LP | 632,168 | $1.53M | 0.0% | -11.4% | 0.907% | |
Data available starting January 2016
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Read More on Synlogic
Volume
6,549 shs
Average Volume
83,866 shs
Market Capitalization
$7.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.49
Who are the company insiders with the largest holdings of Synlogic?
Synlogic's top insider investors include:
- Pfizer Inc (Major Shareholder)
- Antoine Awad (COO)
- Aoife Brennan (Insider)
- Mary Beth Dooley (Insider)
- Michael Vangsted Jensen (CFO)
- Jon Irvin (VP)
- Richard P Shea (Director)
- Michael Powell (Director)
- Paul Francis Miller (Insider)
Learn More about top insider investors at Synlogic.
